Merck paying $950 million to settle US Vioxx criminal, civil charges
This article was originally published in Scrip
Executive Summary
Merck has agreed to plead guilty to violating the Food, Drug and Cosmetic Act (FDCA) and pay $950 million to settle US criminal charges and civil claims for off-label promotion of its cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug Vioxx (rofecoxib), the US Department of Justice (DOJ) and the company said on 22 November.